Rezolute Inc.

Address: 275 Shoreline Drive Suite 500

Sponsor Overview

assignment

Specializations

Congenital Hyperinsulinism and Hypoglycemia

Rezolute Inc. focuses on clinical research in hypoglycemia associated with congenital hyperinsulinism, with attention to stabilizing blood glucose in patients affected by excessive insulin secretion. Its studies address the management of recurrent low blood sugar and the need for improved glycemic control.

Continuous glucose management
Hypoglycemia reduction
Glucose requirements

The research activity in this area is centered on improving day-to-day metabolic stability for individuals living with this rare endocrine disorder.

Tumor-associated Hyperinsulinism

The sponsor also investigates tumor-associated hyperinsulinism, a condition linked to abnormal insulin production by tumors and resulting hypoglycemia. This area of interest reflects a therapeutic focus on endocrine complications arising from neuroendocrine and other hormone-producing tumors.

Hormone-mediated hypoglycemia
Insulin dysregulation
Tumor-related metabolic disorders

Clinical research in this domain is directed toward reducing low blood sugar episodes associated with abnormal hormone secretion.

Endocrine and Metabolic Disorders

Rezolute’s trial portfolio is concentrated in rare endocrine and metabolic disease research, with a strong emphasis on disorders that disrupt normal glucose regulation. The sponsor’s clinical interests are closely tied to conditions where excessive insulin activity contributes to persistent hypoglycemia.

Glucose regulation
Insulin-mediated disorders
Rare metabolic disease

Its research landscape remains narrowly focused on therapeutic areas where control of glycemic variability is central to patient care.

Trial Name	Country	Status
Efficacy and Safety Evaluation of Anti-(Insulin Receptor) Human Monoclonal Antibody RZ358 in Congenital Hyperinsulinism-Associated Hypoglycemia	Bulgaria Denmark France Germany Greece Spain	Not Recruiting
Efficacy and Safety Evaluation of Ersodetug in Tumor-Associated Hyperinsulinism with Inadequately Controlled Hypoglycemia: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial	France The Netherlands	Recruiting